直接抗病毒药物治疗丙型肝炎病毒清除后肝细胞癌的短期风险
这项大规模多中心队列研究纳入1675例经无干扰素索非布韦方案获得持续病毒学应答的丙型肝炎患者,分为既往有肝细胞癌组(152例)和无肝细胞癌组(1523例)。中位随访17个月,46例(2.7%)发生肝细胞癌。肝硬化患者中,治疗结束时血清甲胎蛋白水平和既往肝细胞癌特征是预测新发或复发肝细胞癌的有用标志物。
要点
- 中位随访17个月,1675例患者中46例(2.7%)发生肝细胞癌。
- 肝硬化组1年新发肝细胞癌累积率4.9%,非肝硬化组0.4%(P<0.001)。
- 肝硬化患者治疗结束时甲胎蛋白≥9.0 ng/mL组1年新发肝细胞癌累积率13.1%,<9.0 ng/mL组1.4%(P<0.001)。
核心结论
- 肝硬化患者清除丙型肝炎病毒后,治疗结束时血清甲胎蛋白水平和既往肝细胞癌特征可能是有用的预测新发或复发肝细胞癌的标志物。
研究设计与样本
- 这项大规模多中心队列研究纳入1675例连续接受无干扰素索非布韦方案治疗并获得持续病毒学应答的患者,分为既往有肝细胞癌组(152例)和无肝细胞癌组(1523例)。
主要发现
- 中位随访17个月期间,46例(2.7%)患者发生肝细胞癌。
- 非肝硬化组和肝硬化组1年新发肝细胞癌累积率分别为0.4%和4.9%(log-rank检验P<0.001)。
- 肝硬化患者中,治疗结束时血清甲胎蛋白<9.0 ng/mL组和≥9.0 ng/mL组1年新发肝细胞癌累积率分别为1.4%和13.1%(log-rank检验P<0.001)。
- 非肝硬化组和肝硬化组1年肝细胞癌复发累积率分别为6.5%和23.1%(log-rank检验P=0.023)。
- 肝硬化患者中,既往肝细胞癌特征与肝细胞癌复发显著相关;性别、年龄和代谢特征不影响新发或复发肝细胞癌。
关键数值与推荐
- 肝硬化患者治疗结束时血清甲胎蛋白水平是预测新发肝细胞癌的最强预测因素,截断值为9.0 ng/mL。
临床怎么用
- 对于清除丙型肝炎病毒后的肝硬化患者,治疗结束时血清甲胎蛋白水平和既往肝细胞癌特征可能是有用的预测新发或复发肝细胞癌的标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With the development of direct-acting anti-virals (DAAs), almost all patients with chronic hepatitis C virus (HCV) infection can achieve sustained viral response (SVR). AIM: To evaluate the short-term risk of HCC among patients with SVR by DAAs, including those with cirrhosis or previous HCC. METHODS: This large-scale, multicentre cohort study included 1,675 consecutive patients who achieved SVR by treatment with interferon-free sofosbuvir-based regimens, divided into groups with (n = 152) or without previous HCC (n = 1,523). The Kaplan-Meier method and Cox proportional hazard analysis were used to calculate the cumulative HCC incidence and related factors of HCC. RESULTS: During the follow-up period (median: 17 months), 46 (2.7%) patients developed HCC. The 1-year cumulative rates of de novo HCC were 0.4% and 4.9% for the noncirrhosis and cirrhosis groups respectively (log-rank test: P < 0.001). For cirrhotic patients, serum α-fetoprotein level at the end of treatment (EOT-AFP) was the strongest predictor of de novo HCC. The 1-year cumulative de novo HCC rates were 1.4% and 13.1% in the EOT-AFP < 9.0 ng/mL and ≥ 9.0 ng/mL groups (cut-off value) respectively (log-rank test: P < 0.001). The 1-year cumulative rates of HCC recurrence were 6.5% and 23.1% for the noncirrhosis and cirrhosis groups respectively (log-rank test: P = 0.023). For cirrhotic patients, previous HCC characteristics were significantly associated with HCC recurrence. In contrast, sex, age and metabolic features did not influence de novo HCC or recurrence. CONCLUSIONS: For cirrhotic patients after elimination of HCV, serum EOT-AFP level and previous HCC characteristics would be useful markers for predicting de novo HCC or recurrence.
引用
- Ogawa E, Furusyo N, Nomura H, et al. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment. Aliment Pharmacol Ther. 2017. PMID: 29035002. doi:10.1111/apt.14380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。